Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05266716 · ClinicalTrials.gov registry record · NA

Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

A NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.

Completed
Registry status
NA
Development phase
79
Enrollment target
1
Study location

NCT05266716 is a NA study of Methamphetamine Abuse that has completed, run by Affect Therapeutics. The registered enrollment target is 79 participants, below the 204-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05266716, a NA study of Methamphetamine Abuse, has completed, sponsored by Affect Therapeutics.

COMPLETED
Registry status
NA
Development phase
79 participants
Enrollment target
1
Study location

Study Summary

The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of the Affect app that enhance engagement of participants in the study toward the goal of improving patient outcomes, including reduction/cessation of stimulant use.

Conditions Studied

Interventions

  • BEHAVIORAL Affect Methamphetamine Treatment Program

Study Locations (1)

New York

  • Affect Therapeutics - New York

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2021-02-18
Est. Completion 2022-01-07
Phase NA

Sponsor

Affect Therapeutics

2 total trials

What the Registry Record Tells You About NCT05266716

The ClinicalTrials.gov registry entry for NCT05266716 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (61% lower). The listed sponsor is Affect Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Methamphetamine Abuse appearing as the primary indexed condition, and to 1 intervention - of which Affect Methamphetamine Treatment Program is the first listed.

NCT05266716 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05266716 about?

NCT05266716 is a clinical study titled "Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder". The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of th...

What is the current status of trial NCT05266716?

This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2021-02-18. Estimated completion is 2022-01-07.

What conditions does trial NCT05266716 study?

This clinical trial studies the following conditions: Methamphetamine Abuse.

What interventions are being tested in trial NCT05266716?

The interventions under investigation include: Affect Methamphetamine Treatment Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05266716?

This trial is sponsored by Affect Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05266716 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Methamphetamine Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.